Search

Displaying results 6441 - 6450 of 9865 in total
  1. Drug

    AEF0117

    go.drugbank.com/drugs/DB27675
    Investigational

    AEF0117 is a small molecule drug. AEF0117 is under investigation in clinical trial NCT05554926 (Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects).

  2. Drug

    NGM707

    go.drugbank.com/drugs/DB28351
    Investigational

    NGM707 is a humanized IgG antibody with specificity for both LILRB1 and LILRB2.

  3. Drug

    Enristomig

    go.drugbank.com/drugs/DB29060
    Investigational

    INBRX-105 is a biologic drug.

  4. Drug

    Tovecimig

    go.drugbank.com/drugs/DB30220
    Investigational

    NOV1501 is a biologic drug. … NOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended

  5. Drug

    Lutetium (177Lu) NeoB

    go.drugbank.com/drugs/DB30389
    Investigational

    Lutetium (177Lu) NeoB is a biologic drug.

    Synonyms: Lu-NeoB, [177Lu]Lu-NeoB
  6. Drug

    ARI-0001

    go.drugbank.com/drugs/DB30635
    Investigational

    ARI-0001 is a biologic drug. ARI-0001 is under investigation in clinical trial NCT05641428 (Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL).

  7. Drug

    Triplizumab

    go.drugbank.com/drugs/DB30669
    Investigational

    triplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized

  8. Drug

    FRAX1036

    go.drugbank.com/drugs/DB31834
    Experimental

    FRAX1036 is a p21-activated kinase (PAK) inhibitor.

  9. Drug

    MF-300

    go.drugbank.com/drugs/DB32060
    Investigational

    As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]

  10. Drug

    AAV8-RK-RetGC

    go.drugbank.com/drugs/DB32389
    Experimental

    AAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.